Dessn raises $6M for its production focused design tool
Dessn secures $6M in funding to develop AI-powered design tools integrated with production codebases.
Read on TechCrunch →
Medvolt AI is leveraging OpenAI-enabled intelligence to significantly accelerate the drug discovery process, aiming to reduce experimental cycles and identify promising molecules faster.
Why it matters
This article highlights a crucial application of AI in a high-impact sector: healthcare. By using OpenAI's capabilities to streamline drug discovery, Medvolt AI addresses a long-standing challenge of time, cost, and failure rates in pharmaceutical research. This advancement could lead to faster development of new treatments, potentially saving lives and improving global health outcomes by making life-saving drugs more accessible sooner.
A company called Medvolt AI is using smart AI tools from OpenAI to speed up how new medicines are found. This means they can test ideas faster and pick the best ones more quickly, which could lead to new drugs being available to people much sooner and at a lower cost.
Dessn secures $6M in funding to develop AI-powered design tools integrated with production codebases.
Read on TechCrunch →AI voice startup Vapi has achieved a $500 million valuation following a significant funding round, driven by the increasing adoption of AI agents for customer support and sales calls.
Read on TechCrunch →Thinking Machines is developing an AI model that can process input and generate responses simultaneously, aiming for a more natural, conversational interaction akin to a phone call rather than a sequential text exchange.
Read on TechCrunch →